IP Library Granted Patent US 7,781,554
Granted Patent B2
US 7,781,554 · App. 12/042,378 · Granted Aug 24, 2010

Polysiloxanes and polysiloxane prepolymers with vinyl or epoxy functionality

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,781,554
App. No.
12/042,378
Granted
Aug 24, 2010
Kind
B2
Abstract

Polysiloxanes having vinyl or epoxy functionality. The polysiloxanes are used to form polymer-based materials having properties particularly suited for biomedical device applications. The polysiloxanes are of general formula I: wherein R is a C 2-10 alkenyl, a C 2-10 alkyl with an epoxy group or a C 5 -C 7 cycloalkyl with an epoxy group; R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, optionally substituted phenyl and optionally substituted benzyl; A is —OH or —NHR 5 , wherein R 5 is hydrogen or a C 1-3 alkyl; and B is —R 1 -A or —R 6 , wherein R 1 is a linking group having an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages; and R 6 is selected from the group consisting of C 1-4 alkyl, optionally substituted phenyl or optionally substituted benzyl; and m and n are integers with an m:n ratio from 30:1 to 3:1.

Claims (57)

1. A polysiloxane of general formula I:

wherein

R is a C 2-10 alkenyl, a C 2-10 alkyl with an epoxy group or a C 5 -C 7 cycloalkyl with an epoxy group;

R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, optionally substituted phenyl and optionally substituted benzyl;

A is —OH or —NHR 5 , wherein R 5 is hydrogen or a C 1-3 alkyl; and

B is —R 1 -A or —R 6 , wherein R 1 is a linking group having an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages; and R 6 is selected from the group consisting of C 1-4 alkyl, optionally substituted phenyl and optionally substituted benzyl; and

m and n are integers with an m:n ratio from 30:1 to 3:1.

2. The polysiloxane of claim 1 wherein R is a C 2 -C 10 alkenyl.

3. The polysiloxane of claim 1 wherein R is a C 2-10 alkyl having at least one epoxy group or a C 5 -C 6 cycloalkyl having at least one epoxy group.

4. The polysiloxane of claim 1 wherein the m:n ratio is from 20:1 to 8:1, and the polysiloxane has a number average molecular weight from 2000 to 10,000.

5. The polysiloxane of claim 1 wherein A is —OH.

6. The polysiloxane of claim 2 wherein R is selected from the group consisting of —CH═CH 2 , —CH 2 —CH═CH 2 , —CH 2 —CH 2 —CH═CH 2 —CH 2 —C 5 H 7 and —CH 2 —C 6 H 9 .

7. The polysiloxane of claim 1 wherein R 1 is independently represented by formula S or formula T,

wherein x is any integer from 1 to 6, y is any integer from 2 to 6, and R a and R b are each independently selected from hydrogen, fluorine or methyl.

8. The polysiloxane of claim 7 wherein R 1 is represented by formula S, x is 3 or 4 and R 2 , R 3 and R 4 are independently selected from methyl, ethyl or phenyl.

9. The polysiloxane of claim 3 wherein R is a C 2 -C 4 alkylepoxy selected from the group consisting of

10. A silicone prepolymer of general formula II:

wherein

R is a C 2-10 alkyl with an epoxy group or a C 5 -C 7 cycloalkyl with an epoxy group;

R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, optionally substituted phenyl and optionally substituted benzyl;

m and n are integers with an m:n ratio from 30:1 to 3:1;

R 1 is an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages;

D is defined by -U-L-M, wherein U is a urethane or urea link, L is an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages, and M is an activated polymerizable group; and

E is defined by —R 1 -D or —R 6 , wherein R 6 is selected from the group consisting of C 1-4 alkyl, optionally substituted phenyl and optionally substituted benzyl.

11. The silicone prepolymer of claim 10 wherein R is a C 2 -C 4 alkylepoxy selected from the group consisting of

12. The silicone prepolymer of claim 10 wherein E is —R 1 -D.

13. The silicone prepolymer of claim 10 with a number average molecular weight from 16,000 to 60,000.

14. A silicone prepolymer of general formula IV:

wherein

R is a C 2-10 alkenyl;

R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, optionally substituted phenyl and optionally substituted benzyl;

m and n are integers with an m:n ratio from 30:1 to 3:1;

R 1 is an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages;

D is defined by -U-L-M, wherein U is a urethane or urea link, L is an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages, and M is an activated polymerizable group; and

E is defined by —R 1 -D or —R 6 , wherein R 6 is selected from the group consisting of C 1-4 alkyl, optionally substituted phenyl or optionally substituted benzyl.

15. The silicone prepolymer of claim 14 wherein R is selected from the group consisting of —CH═CH 2 , —CH 2 —CH═CH 2 , —CH 2 —CH 2 —CH═CH 2 , —CH 2 —C 5 H 7 and —CH 2 —C 6 H 9 .

16. The silicone prepolymer of claim 14 wherein E is —R 1 -D.

17. The prepolymer of claim 14 with a number average molecular weight from 16,000 to 60,000.

18. A polysiloxane prepolymer comprising siloxane segments (HS) and (MH)

(*Dii*Diol*Dii*PS) x (HS)

(*Dii*PS) y (MH)

wherein:

each Dii is independently a diradical residue of a diisocyanate;

each Diol is independently a diradical residue of a diol having 1 to 10 carbon atoms;

each * is independently —NHC(O)NH—, —NHC(O)O— or —OC(O)NH—;

x represents the number of segments (HS) and is at least 2;

y represents the number of segments (MH) and is at least 1; and

each PS is independently a diradical residue of a polysiloxane of formula

wherein

R is a C 2-10 alkenyl, a C 2-10 alkyl with an epoxy group or a C 5 -C 7 cycloalkyl with an epoxy group;

R 1 is a linking group having an alkylene group with 2 to 8 carbon atoms wherein the alkylene group optionally includes ether, urethane or ureido linkages;

R 2 , R 3 and R 4 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, optionally substituted phenyl and optionally substituted benzyl;

A is —OH or —NHR 5 , wherein R 5 is hydrogen or a C 1-3 alkyl; and

m and n are integers with an m:n ratio from 30:1 to 3:1.

19. The polysiloxane prepolymer of claim 18 wherein R 1 is independently represented by formula S or formula T,

x is any integer from 1 to 6, y is any integer from 2 to 6, and R a and R b are each independently selected from hydrogen, fluorine or methyl.

20. The polysiloxane prepolymer of claim 19 wherein R 1 is represented by formula S, x is 3 or 4 and R 2 , R 3 and R 4 are independently selected from methyl, ethyl or phenyl.

Assignments (30)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 031156/0508) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061778/0446 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Nov 1, 2010
From: WP PRISM INC.; BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 025227/0143 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2008
From: LAI, YU-CHIN; QUINN, EDMOND T.; LANG, WEIHONG; NUNEZ, IVAN M.
To: BAUSCH AND LOMB INCORPORATED
Reel/Frame 020601/0463 →